Content area
Full Text
To the Editor: Eggermont and colleagues (Nov. 10 issue)1 found that ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was associated with significantly higher survival rates than placebo when given as adjuvant therapy for stage III melanoma.
The anticancer effect of ipilimumab was shown to be influenced...